Fifth Third Bancorp Acquires 8,610 Shares of Boston Scientific Corporation $BSX

Fifth Third Bancorp grew its stake in Boston Scientific Corporation (NYSE:BSX) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 304,656 shares of the medical equipment provider’s stock after purchasing an additional 8,610 shares during the period. Fifth Third Bancorp’s holdings in Boston Scientific were worth $29,744,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of BSX. Steph & Co. acquired a new position in Boston Scientific during the third quarter worth $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $25,000. Murphy & Mullick Capital Management Corp increased its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter valued at about $26,000. Finally, United Community Bank boosted its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.8%

Shares of BSX opened at $74.72 on Tuesday. The stock’s fifty day simple moving average is $90.56 and its 200-day simple moving average is $97.35. The firm has a market capitalization of $110.76 billion, a PE ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $72.69 and a 12-month high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BSX shares. TD Cowen dropped their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th. Royal Bank Of Canada cut their price objective on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Sanford C. Bernstein restated an “outperform” rating and set a $112.00 target price on shares of Boston Scientific in a report on Friday, February 6th. Finally, Truist Financial cut their price target on Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $109.43.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.